Efficacy and safety of tirofiban in patients with acute coronary syndrome undergoing percutaneous coronary intervention
- VernacularTitle:国产替罗非班治疗急性冠状动脉综合征的临床研究
- Author:
Yuqing HOU
;
Zhongjiang ZHOU
;
Jianyong LI
- Publication Type:Journal Article
- Keywords:
Coronary disease;
Tirofiban;
Treatmeant outcome
- From:
Chinese Journal of Interventional Cardiology
1996;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of tirofiban in acute coronary syndrome(ACS)patients during primary PCI.Methods Sixty two patients with ACS who underwent primary PCI were randomly divided into two groups which were:the tirofiban + PCI group(n=32)and the primary PCI group(n=30).Tirofiban was predominantly initiated in the catheter laboratory before or during the intervention and maintained for a mean of 30 h(10 ?g/kg for bolus,followed by 0.15 ?g/kg?min infusion).Platelet counting,MACE event and periprocedural complication were investigated.Heart function by echo was observed.Results The incidence of the major primary end point(refractory ischemia,new myocardial infarction and death)at 30 days was significantly lower in the tirofiban group than that in the placebo group(9.3% vs 20.0%,P
